Daily Biotech Movers — 2026-09-28: A Phase 3 Win and a Take-Private Carried the Index — and the Standard Deviation — While the Median Name Fell

Monday, September 28, 2026 was the first session in three in which the small-cap biotech complex beat everything else on the board — and the first in a while in which the headline statistics were almost entirely the work of two stocks. Across 572 tracked public biotech and life-sciences companies, 273 finished higher against 286 decliners — a decliner-to-advancer ratio of 1.05-to-1, by far the narrowest of the last three sessions after 1.35-to-1 on Thursday and 1.82-to-1 on Friday. The median move was -0.13% and the mean -0.12%, with a standard deviation of 8.98%. 81 companies moved at least 5% — up from 60 on Friday — and 101 were anomaly-flagged once volume-only spikes are counted, against 75 on Friday.

Those headline numbers are honest and slightly misleading, and the correction is the most useful thing on this page. Strip out a single stock — Kodiak Sciences, up 177.96% — and the cross-sectional standard deviation collapses from 8.98% to 4.88%, while the mean falls from -0.12% to -0.44%. The median barely moves (-0.13%), because a median is supposed to be robust to outliers. In other words: the tape looked flat and looked violent for the same reason, and that reason was one $90 equity that gained $57.57 in six and a half hours. Underneath it, the typical tracked company lost an eighth of a percent on a day when the small-cap biotech index proxy rose 1.04% and the broad healthcare proxy rose 0.33% while the S&P 500 proxy fell 0.75%.

That is the shape of the day: a market that paid up for two events and left everything else alone. A pivotal Phase 3 win and a signed take-private produced the two largest prints on the board — +177.96% on 49.96x volume and +55.24% on 28.23x volume — and both carried the institutional footprint of real capital repricing a real outcome. On the other side, the three worst performers fell for three different reasons that had nothing to do with each other: a clinically positive readout the market priced as a disappointment, a listing deadline, and the third leg of a prior-cycle unwind.

The Distribution

Measure	September 28 reading	September 25 reading
Tracked / priced	572	572
Directional moves	559 (273 up, 286 down)	558 (198 up, 360 down)
Up / down ratio	1.05-to-1 decliners	1.82-to-1 decliners
Mean / median	-0.12% / -0.13%	-0.98% / -0.82%
Standard deviation	8.98% (4.88% excluding Kodiak)	3.71%
Average advancer / decliner	+3.12% / -3.20%	+2.09% / -2.70%
Price moves of at least 5%	81	60
Anomaly-flagged (incl. volume-only)	101	75
Stealth names (|move| < 3% on 3x+ volume)	0	3

Three features matter. First, breadth improved sharply — 273 advancers against Friday’s 198, and 81 moves of 5% or more against 60 — while the median stayed negative. That combination, more advancers and fatter tails but no improvement in the typical name, is what an event-driven tape looks like: the amplitude is real, the participation is concentrated. Second, the distributions are not comparable across the two days because of Kodiak alone; the honest comparison is the ex-Kodiak column. Third, the stealth set was empty for the first time in weeks — no name cleared a 3x volume filter while holding a move under 3%, which suggests the unusual turnover went into price rather than into quiet accumulation.

The sector table tells the same story at group level, and it is a warning about averages. Generic Drugs +2.74% (n=5) and Genetics & Genomics +2.18% (n=7) led the small buckets, but the headline is Biologics +1.85% (n=84) — the second-largest bucket in the tracked universe — where the median was -0.09%. Kodiak Sciences is categorised inside that bucket, and removing it takes Biologics from +1.85% to -0.27%. The same distortion runs in the other direction at the bottom: Stem Cells and Cellular Therapy -4.12% (n=21) is the worst bucket on the board, and removing Adicet Bio alone takes it to -2.85%. Two individual stocks defined both ends of a 24-bucket table. The genuinely broad weakness sat in Diagnostics -1.28% (n=30), Devices - Implants -1.56% (n=10), Devices - Miscellaneous -1.18% (n=26) and AI / Machine Learning -2.50% (n=6) — with Small Molecule Pharma, the largest bucket at n=146, essentially unchanged at -0.11% on a median of +0.31%.

The 6 Classes of Mover Signal

1. Halt-release and reverse-split-adjacent mechanics. Present, and it explains the second-worst print on the board. NeuroSense Therapeutics (-26.76% on 2.50x) is a 1-for-20 reverse-split-adjusted equity marking against a listing deadline that arrives tomorrow. LeonaBio (-11.69% on 16.58x) is the same class in its dilution form — the third consecutive session of that unwinding. Adagio Medical (-12.46%) continued its post-restructuring slide, now at $0.17 with five-day momentum of -59.59%.

2. Single-stock clinical, regulatory or commercial catalyst. Present, and it produced the largest print of the day by a wide margin. Kodiak Sciences (+177.96% on 49.96x) moved on same-day pivotal Phase 3 topline results in wet age-related macular degeneration — the textbook Class 2 event, disclosed before the open with a filing timeline attached. The class also appears on the losing side without a fresh disclosure: Adicet Bio (-29.60% on 13.77x) reported positive Phase 1 lupus data the same morning and fell, which is Class 2 data processed by the tape as Class 5. Ocular Therapeutix (-20.67% on 6.85x) and MediciNova (-18.60%) cleared anomaly thresholds with no same-day release in the mix.

3. Buyout and strategic capital. Present, and it produced the day’s cleanest institutional print after Kodiak. Lifecore Biomedical (+55.24% on 28.23x) traded 4.0 million shares after signing a definitive agreement to be acquired by Webster Equity Partners for $6.28 per share in cash plus one non-tradable contingent value right, a transaction valued at up to $663.7 million assuming full milestone achievement. A 49.5% premium to Friday’s close, a 30-day go-shop and a close expected by year-end is what a documented take-private looks like in the tape, and the stock closed 3.8% above the cash consideration because the CVR leg still has a price.

4. Sector rotation. Present, and it ran the other way from Friday. The XBI +1.04% against XLV +0.33% and SPY -0.75% trio is the mirror image of Friday’s XLV +0.50% against XBI -0.65%, and the sector table agrees from the inside: the two buckets that lost every slot on Friday — small-molecule pharma and biologics — were flat-to-up in median terms, while the devices and diagnostics complex that led Friday led nothing today. Capital moved back toward the high-beta, pre-revenue end of healthcare for one session.

5. Sell-the-news and prior-cycle profit-taking. Present, and it supplied two of the three worst prints. Profusa (-22.48% on 0.22x) gave back part of a +41.46% session from September 24 on less than a quarter of normal volume — the third leg of a round trip in a $1.69 equity. Vistagen Therapeutics (+8.79% on 0.26x), Actuate Therapeutics (+8.26% on 0.64x) and Filana Therapeutics (+14.05% on 0.51x) show the class moving in the other direction: three of the day’s larger gainers advanced on below-average turnover. Surrozen (-12.29%) and Artelo Biosciences (-12.19%) continued last week’s unwind.

6. Stealth accumulation and distribution. Absent. Zero names cleared a 3x volume filter while holding a move under 3% — the third time this month the category has come up empty, and a reminder that the volume anomaly list and the price leaderboard are currently the same list, which makes the paper trail and the press release the only real differentiators.

Top 3 Winners — What Drove Them

KOD — Kodiak Sciences — +177.96% on 49.96x volume

Kodiak closed at $89.92 on 38,512,470 shares — 49.96x its 30-day average, against a $32.35 prior close, having traded a $60.50–$95.77 range that opened roughly 87% higher, with five-day momentum of just -1.1% — the entire move happened inside this session, and the close sits about 88% above the previously recorded 52-week high of $47.84. Signal class: Class 2 single-stock clinical catalyst — pivotal, same-day and fully disclosed. At 6:30 AM ET the company reported topline results from DAYBREAK, its pivotal Phase 3 study of Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in wet age-related macular degeneration Kodiak Sciences — Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial; PR Newswire — same release; EyeWire — Kodiak Reports Phase 3 DAYBREAK Trial Meets Primary Endpoints for Zenkuda in Wet AMD. Zenkuda met its primary endpoint at a p-value of 0.0007, demonstrating non-inferiority in vision gains versus aflibercept at year one, with 54% of patients reaching six-month durability under strict treat-to-dryness real-world retreatment criteria; tabirafusp-ted met the vision endpoint at p=0.0036 and the anatomical key secondary endpoint at p<0.0001 RTTNews — Kodiak Sciences Reports Positive Phase 3 DAYBREAK Results; MarketScreener — Kodiak Sciences announces DAYBREAK results. Safety is the second half of the re-rating: a 0% intraocular inflammation rate and a 0.5% cataract adverse-event rate for Zenkuda against 0.9% for the aflibercept comparator Healio — Two investigational agents for wet AMD meet Phase 3 primary endpoints; Grafa — Kodiak Reports Zenkuda Phase 3 Wet AMD Results. The company now plans a multi-indication BLA in the fourth quarter of 2026 covering five positive Phase 3 studies — DAYBREAK and DAYLIGHT in wet AMD, GLOW and GLOW2 in diabetic retinopathy, and BEACON in retinal vein occlusion — which converts six years of clinical disappointment into a regulatory calendar. Nearly 50x normal turnover on a $90 equity is institutional repricing with a filing date attached.

LFCR — Lifecore Biomedical — +55.24% on 28.23x volume

Lifecore closed at $6.52 on 4,008,566 shares — 28.23x its 30-day average, against a $4.20 prior close, in a tight $6.40–$6.64 range, with five-day momentum of -5.83%. Signal class: Class 3 buyout / strategic capital — a signed definitive agreement. Before the open the company announced it has entered a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million assuming full achievement of performance milestones: $6.28 per share in cash at closing, plus one non-tradable contingent value right per share Lifecore Biomedical — Lifecore Biomedical to be Acquired by Webster Equity Partners; GlobeNewswire — same release; RTTNews — Lifecore Biomedical To Be Taken Private By Webster Equity Partners. The cash consideration is an approximately 49.5% premium to Friday’s close, and the CVR leg is milestone-weighted: $30 million for 2028, $45 million for 2029 and $85 million for 2030, up to $160 million in aggregate StockTitan — Lifecore Biomedical agrees to $6.28-a-share sale, 8-K filing; InsideArbitrage — Webster Equity Partners to Acquire Lifecore Biomedical for $663.70 Million. The agreement carries a 30-day go-shop period and is expected to close by the end of 2026 Seeking Alpha — Lifecore Biomedical to be acquired by Webster Equity Partners. Ademi LLP published a shareholder alert the same morning investigating whether the buyout fairly values the company, which is a routine companion filing rather than a signal Morningstar — LFCR Shareholder Alert. This is a revenue-generating CDMO being taken private, and the tape priced it as arbitrage: the close held 3.8% above the cash price, with the CVR carrying the rest.

NAUT — Nautilus Biotechnology — +15.30% on 4.44x volume

Nautilus closed at $1.11 on 4,091,004 shares — 4.44x its 30-day average, against a $0.9627 prior close, in a $0.99–$1.17 range, with five-day momentum of -0.34% and the shares sitting in the bottom tenth of a 52-week range running from $0.78 to $4.31. Signal class: no clean same-day catalyst — Class 1 mechanical flow. Nothing was published: the company’s disclosure record stops at a September 4 Nature Methods paper describing the first large-scale, single-molecule analysis of the tau proteoform landscape on its platform Nautilus Biotechnology — Nature Methods Publication Reveals Deep Insights into Functional Biology; Yahoo Finance — Nature Methods publication. The only September capital-markets event is a September 11 sales agreement with TD Securities (USA) / TD Cowen for an at-the-market programme of up to $125 million — a facility whose timing the company controls, and therefore not a catalyst TipRanks — Nautilus Biotechnology Establishes New At-The-Market Offering. The fundamental backdrop is unchanged: Q2 2026 recognised the company’s first revenue with operating expenses down and a cash runway into 2028, and R&D priority has shifted toward proteoform applications Nautilus Biotechnology — Reports Second Quarter 2026 Financial Results. A +15.3% session on 4.4x volume in a $1.11 name, two sessions before quarter-end, with no disclosure attached, is flow rather than information. No clean catalyst — flagged.

Top 3 Losers — What Drove Them

ACET — Adicet Bio — -29.60% on 13.77x volume

Adicet closed at $6.35 on 2,145,135 shares — 13.77x its 30-day average, against a $9.02 prior close, trading a $6.25–$7.96 range and finishing 5.7% above the recorded 52-week low of $6.01, with five-day momentum of -1.74%. Signal class: Class 2 single-stock clinical catalyst that the tape processed as Class 5 sell-the-news — data that cleared the clinical bar and failed the commercial one. At 8:00 AM ET the company reported updated Phase 1 data for prula-cel (formerly ADI-001), its off-the-shelf allogeneic gamma-delta CAR-T, in 22 efficacy-evaluable patients with systemic lupus erythematosus — 16 with lupus nephritis and six with extra-renal SLE Business Wire — Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel Study; Adicet Bio — same release. At 12 months, 12 of 22 evaluable patients — 54% — achieved DORIS remission, and eight of 16 evaluable lupus-nephritis patients — 50% — achieved complete renal response, after a single dose, off immunosuppression, with biological evidence of an immune reset Finviz — Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data; Grafa — Adicet Bio Reports Prula-Cel Lupus Trial Data. The safety package is the differentiator the field has been waiting for: no cases of IEC-HS, no ICANS and CRS almost entirely grade 1, against the hyperinflammatory deaths that halted a large pharma CD19 autoimmune CAR-T and the inflammatory events that paused another Fierce Biotech — Adicet Bio CAR-T sparks lupus remissions in early-stage trial; Seeking Alpha — Adicet Bio Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis. The pivotal study is slated to begin in the fourth quarter of 2026. So why -29.6%? Because the shares had been bid up roughly 9% on Friday on nothing but the announcement of a Monday webcast, and expectations in this class have re-based on durability of drug-free remission and the reliability of B-cell depletion — the two variables a small Phase 1 cannot establish Biotech Insider — Adicet’s Lupus CAR-T Data Lands and ACET Drops 29.6%; talk.bio — Adicet reports encouraging early lupus CAR-T data as shares fall; AInvest — Adicet Bio Trades for Less Than Its Cash. 13.8x normal turnover is the institutional tell: a deliberate repricing taken with the full dataset in hand, and it left the shares within 6% of their low.

NRSN — NeuroSense Therapeutics — -26.76% on 2.50x volume

NeuroSense closed at $5.09 on just 61,676 shares — 2.50x its 30-day average, against a $6.95 prior close, in a $4.99–$7.15 range that printed a new 52-week low beneath the previously recorded $5.00 floor, with five-day momentum still +9.45% — the prior week’s entire advance handed back in one session. Signal class: Class 1 — reverse-split-adjacent listing mechanics with going-concern arithmetic underneath. The calendar is the catalyst. Under deficiency notices dated April 2, 2026 for failing the $1.00 minimum bid price and $35 million minimum market value of listed securities requirements, the company had until September 29, 2026 — tomorrow — to regain compliance, and it effected a 1-for-20 reverse share split on September 14, 2026 with a new CUSIP as the cure attempt StockTitan — NeuroSense Gets Nasdaq Compliance Notice, Sept. 29 Deadline; NasdaqTrader — Equity Corporate Actions Alert #2026-656, 1-for-20 reverse split effective September 14, 2026; TipRanks — NeuroSense Therapeutics Faces Nasdaq Deficiency Notices. The half-year balance sheet published on September 25 is the more binding constraint: cash and cash equivalents of $231 thousand at June 30 against total current liabilities of $2,999 thousand, with the company stating it continues to pursue financing and to evaluate strategic alternatives including potential business and corporate transactions NeuroSense Therapeutics — Provides Business Update and Progress for the First Half of 2026; PR Newswire — same release. The science is not what the tape is pricing: PrimeC in ALS is targeting a December 2026 New Drug Submission in Canada after completing the pre-NDS process, on a Phase 2b PARADIGM package whose long-term follow-up reported a statistically significant 65% reduction in the risk of death and an estimated median survival of 36.3 months versus 21.4 months. But 61,676 shares is not a market making a judgement about data — it is a $5 equity being marked against a listing deadline with $231 thousand in the bank. Mechanical / prior-cycle — flagged.

PFSA — Profusa — -22.48% on 0.22x volume

Profusa closed at $1.69 on 819,475 shares — 0.22x its 30-day average, against a $2.18 prior close, closing on the session low of a $1.69–$2.01 range and roughly 7% above the recorded 52-week low of $1.58, with five-day momentum still +14.14%. Signal class: Class 5 sell-the-news — the catalyst belongs to a previous session and today is the unwind leg. Nothing was published: the record stops at September 24, when the company announced significant progress towards a CE mark for the Lumee Oxygen Platform with ISO 13485 certification expected in early October. The shares ran +41.46% on that disclosure, gave back -28.05% on Friday and another -22.48% today Profusa — Press Releases; RTTNews — Profusa Advances Lumee Oxygen Platform Toward CE Mark; Nasdaq — Profusa Announces Significant Progress Towards Lumee Oxygen Platform CE Mark. The wording of that release is what is being repriced, and it was explicit at the time: the certification decision advances the platform toward CE marking but does not represent final CE marking, which remains subject to the remaining conformity-assessment activities Yahoo Finance — Profusa ISO 13485 Certification Decision Advances Lumee Oxygen Platform Toward CE Mark; SFBN — Profusa Announces Significant Progress Towards Lumee Oxygen Platform CE Mark. The turnover is the tell: a -22.5% decline on 22% of normal volume is a book with no bid rather than institutional distribution, and the capital structure has not changed — a $350,000 senior secured convertible note priced on September 16 at a $4.28 conversion price now sits roughly 2.5x above the market TradingView — Profusa raises $350,000 via senior secured convertible note. Prior-cycle catalyst — flagged.

The Cross-Cutting Pattern

The pattern is a tape that repriced events and ignored everything else, and the two statistics that make it legible are the ex-Kodiak mean and standard deviation. In a session where 273 of 559 directional names advanced — the best breadth in three sessions — and where the small-cap biotech proxy outperformed the S&P 500 by 1.79 points, the median company still fell -0.13% and the mean excluding Kodiak fell -0.44%. Both statements are true, and together they describe a market with real appetite for binary outcomes and none for the general clinical-stage complex. Monday’s bid was not a rotation into biotech; it was a rotation into resolution — a pivotal readout that finally worked, and a take-private with a go-shop period and a filing date.

That reading is confirmed from the inside by the sector table. The bucket that gained the most on an average basis after the small ones — Biologics, +1.85% on n=84 — has a median of -0.09%, and loses 2.1 points of average when a single name is removed. The bucket that lost the most — Stem Cells and Cellular Therapy, -4.12% on n=21 — loses 1.3 points when a single name is removed. Structurally, then, the distribution was flat in the middle and violent at the edges, with the violence traceable to two disclosures, and the day’s most valuable information is what did not happen: no sector-wide bid, no volume accumulation in quiet names (the stealth set was empty), and no sign that Friday’s specific winners were being re-bought.

The third theme is the asymmetry in what the market rewarded. A pivotal Phase 3 win with a BLA filing date was worth +178%. A signed buyout at a 49.5% premium was worth +55%. A clinically positive Phase 1 with no durability answer and a small n was worth -29.6%, and a pending pivotal study was not enough to hold the stock above its low. Whatever the absolute percentages, the ranking is instructive: in an environment where the financing window is narrow and the median name is being sold, the market is paying for completed de-risking and discounting promised de-risking — which is also why the two names that fell the hardest without news (NeuroSense on a listing clock, Profusa on a prior-cycle spike) fell on turnover that implied an absent bid rather than an active seller.

The 5 Data Points That Matter

1. Percentage change versus the tape. With a -0.13% median, the six leaderboard names are a 15- to 178-point divergence. The two that decoupled hardest from their own group are the same two that distorted it: KOD +177.96% against a Biologics bucket that reads +1.85% including it and -0.27% without it, and ACET -29.60% against a Stem Cells bucket at -4.12% including it and -2.85% without it. LFCR +55.24% and NAUT +15.30% are the cleaner reads precisely because they are single-name events with no sector claim attached.

2. Volume ratio. The two heaviest ratios on the board are the two event prints: KOD at 49.96x on 38.5 million shares and LFCR at 28.23x on 4.0 million shares. Both are volume confirming a fundamental repricing. The outlier of a different kind sits just above them — Scynexis at 113.36x on a +5.24% close on 7.8 million shares, the largest multiple on the board and a smaller price move than the ratio would suggest, which is a repricing in progress rather than a completed one. Then the leaderboard thins sharply: ACET 13.77x, NAUT 4.44x, NRSN 2.50x — and PFSA at 0.22x. A -22.5% session on a fifth of normal turnover is the absence of a bid, not the arrival of a seller.

3. Five-day momentum. This column separates an event from a trend. KOD at -1.1% against a +177.96% day, and LFCR at -5.83% against +55.24%, are both first-day moves out of flat-to-down weeks — the cleanest possible event signature. On the losing side, PFSA at +14.14% against -22.48% and NRSN at +9.45% against -26.76% are two names unwinding inside their own week, while ACET at -1.74% against -29.60% shows that this was not a continuation of a decline: the entire move was made in one session, on one dataset.

4. Position in range and absolute price. Monday’s board spans price bands in a way Friday’s did not: KOD at $89.92 printed a new high and LFCR at $6.52 sits near the top of a $3.62–$8.98 range, while NAUT at $1.11 is in the bottom tenth of its range and ACET at $6.35 closed 5.7% above a $6.01 low that is now within reach again. NRSN printed a new 52-week low intraday at $4.99 and PFSA closed within 7% of its low. The range column is where the day’s split is clearest: the winners are at highs, the losers are at lows, and nothing in the middle moved.

5. Cash and dilution context. This is the differentiator, and it explains both tails. NRSN holds $231 thousand in cash against $3.0 million in current liabilities with a listing deadline the following day. PFSA carries a $350,000 convertible note struck at $4.28 against a $1.69 market. NAUT has an open $125 million at-the-market facility — the reason a +15% day in a $1.11 equity deserves scepticism rather than enthusiasm. ACET trades for less than the cash on its balance sheet, which is precisely why a -29.6% session on positive data reads as a valuation argument rather than a solvency one. Against all of that, KOD is now funded by a BLA path and LFCR is funded by a signed merger. The organising asymmetry of the day is the same one that organised Friday: capital released versus capital required — and on Monday, the market paid a premium for the first and a discount for the second.

The five-point summary: read KOD as a genuine Class 2 pivotal win with a fourth-quarter filing date, and as the single stock that produced the session’s headline statistics; read LFCR as arbitrage pricing a documented take-private at a 49.5% premium with a live CVR; read NAUT as flow in a $1.11 name with an open at-the-market facility and no disclosure; read ACET as positive Phase 1 lupus data that failed the market’s durability bar and returned the shares to within 6% of their low; read NRSN as a listing-clock print on 62,000 shares; and read PFSA as the third leg of a prior-cycle round trip on a fifth of normal volume.

What This Synthesis Will and Won’t Tell You

This is a one-day reading and should be read as one. It tells you what moved and why: the 101 anomaly-flagged names, the six data-defined top movers, the signal class behind each, and the cross-cutting pattern — a tape that paid up for two completed de-risking events while the median tracked company fell, with an empty stealth set, a two-point sector distortion at both ends of the table, and a small-cap biotech proxy that beat the S&P 500 by 1.79 points on the strength of one stock. It does not tell you what happens next: whether Kodiak’s DAYBREAK data convert into a submitted BLA in the fourth quarter and whether the durability claim survives regulatory scrutiny; whether Lifecore’s go-shop period produces a higher bid or expires quietly; whether Adicet’s durability data arrives in the pivotal study that starts this quarter and whether a class that has now produced a safety win can produce a persistence win; whether NeuroSense regains compliance by the September 29 deadline or takes a different route; whether Profusa’s ISO 13485 certification is finalised in early October and converts into CE marking; or whether Nautilus uses the open facility into the strength of a +15% session.

The honest limits are three. The catalyst investigation covers the six data-defined top movers only — the rest of the anomaly board, including Ocular Therapeutix -20.67% on 6.85x volume, Scynexis +5.24% on 113x, MediciNova -18.60%, Insight Molecular Diagnostics -18.88%, Adagio Medical -12.46%, LeonaBio -11.69% on 16.58x and Silexion -4.57% on 73.3 million shares on the downside of the attention line, and Filana +14.05%, Vistagen +8.79%, MacroGenics +8.56% on 4.28x, ADMA Biologics +7.89%, Quanterix +7.65%, Xencor +7.56%, Liquidia +7.66%, MBX Biosciences +7.29%, Taysha +6.85% and Abivax +6.36% on the upside, carries stories that are noted but not investigated. Second, two of the six leaderboard names had no clean same-day catalyst and this synthesis labels them mechanical rather than inventing narratives for them. Third, the day’s headline statistics are not robust to a single observation — the standard deviation, the mean and the Biologics sector average all move materially when Kodiak Sciences is removed, and any reader who quotes the 8.98% dispersion as evidence of a volatile biotech tape is quoting one company’s Phase 3 readout.

---

This is editorial analysis, not investment advice. Single-day returns reflect regular-session closing prices on 2026-09-28 and will change with market conditions, clinical readouts, financing terms, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; readers should review the underlying disclosures before drawing conclusions about momentum durability.

Generated 2026-09-28 PT (post-market, after the 4 PM ET close). Market data compiled from public quote and historical market-data feeds; sector categorization from public company filings and listings; company backgrounds compiled from public investor disclosures and press releases. For the prior synthesis, see Daily Biotech Movers — 2026-09-25.